This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
The Greater Horn of Africa is experiencing one of the worst food insecurity situations in decades. It is estimated
that more than 37 million people are in Integrated Food Security Phase Classification (IPC)1 phase 3 or above and approximately 7 million children under the age of five are acutely mal...nourished in the region. While finding food and safe water is the absolute priority, the health response is essential to avert preventable disease and death.
more
7 April 2022. Aimed at national policymakers, public health and healthcare planners, staff working in reception centres, and healthcare staff caring for displaced persons, the information note concludes that universal testing of incoming refugees from Ukraine for tuberculosis (TB) infection is not r...ecommended. Specific groups, such as household contacts of bacteriologically confirmed pulmonary cases, or those who are immunocompromised should however be considered for TB infection testing.
Available in Czech, Hungarian, Polish, Romanian, Slovakian, Ukranian
more
The Best practice portal is designed to help you find practical and reliable information on what works (and what doesn’t) in the areas of prevention, treatment, harm reduction and social reintegration. It will help you identify tried and tested interventions quickly, allocate resources to what's e...ffective, and improve interventions applying tools, standards and guidelines.
more
The results of the SHINE trial have been published in the NEJM today. SHINE looked at whether treatment for children with minimal TB could be reduced from 6 months to 4 months. It found that the four month treatment was as good as the standard six months treatment for children with minimal TB
The COVID-19 CARE pathway is a living tool to support health care workers visualize the current clinical and therapeutic recommendations to be considered in the care planning for patients with COVID-19.
The COVID-19 CARE pathway is aligned with the eighth version of the WHO Therapeutics and COVID...-19: living guideline published on the 14 January 2022 and the third version of the WHO COVID-19 Clinical management: living guidance published on the 23 November 2021.
more
ournal of Public Health in Africa 2021; volume 12:2009
19 August 2022. A monkeypox case investigation form (CIF) has been designed as a tool for Member States and researchers to conduct in-depth epidemiological investigation of suspected, probable and confirmed cases of monkeypox. This form allows to collect data prospectively or retrospectively for bot...h cases and their contacts. The full form is meant to serve as a tool for in-country use and the data are not required to be reported to WHO.
more
MEDBOX Issue Brief No.17, 21 November 2021
Women's cancers have a significant impact on women's health worldwide. According to the World Health Organisation, nearly three million women are diagnosed with breast or cervical cancer every year. In this Issue Brief you will find more information.
Medicines and medical devices for 10 000 people for approximately three months
WHO has developed a clinical case definition of post COVID-19 condition by Delphi methodology that includes 12 domains, available for use in all settings. This first version was developed by patients, researchers and others, representing all WHO regions, with the understanding that the definition ma...y change as new evidence emerges and our understanding of the consequences of COVID-19 continues to evolve.
Post COVID-19 condition occurs in individuals with a history of probable or confirmed SARS CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms and that last for at least 2 months and cannot be explained by an alternative diagnosis. Common symptoms include fatigue, shortness of breath, cognitive dysfunction but also others and generally have an impact on everyday functioning. Symptoms may be new onset following initial recovery from an acute COVID-19 episode or persist from the initial illness. Symptoms may also fluctuate or relapse over time.
more
Factsheet.
Source: WHO Global Tuberculosis Report 2020
7 June 2022. To treat complications associated with measles: severe complications with module 1 (50 cases) and mild complications with module 8 (20 cases).
The new measles kit 2021 is designed to prepare for and support the treatment of non-severe and severe measles cases during outbreaks. The kit ...provides the essential medicines, supplies and equipment for the management of clinical suspected and severe cases.
more